Coming out of two difficult years in the pandemic, 2022 will be an “outstanding year” for Boston Scientific, according to Angelo De Rosa, the general manager of Boston Scientific’s cardiac rhythm management and electrophysiology businesses in Europe, Middle East and Africa (EMEA).
At the EHRA 2022 Copenhagen & Online Congress in April, the company focused on showing off its electrophysiology portfolio “and the ambition of taking the leadership in the [atrial fibrillation] ablation space
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?